SCHEMBL23922239

SCHEMBL23922239

COP(=O)(CP(=O)(OCc1ccccc1)OCC1OC(n2cnc3c(N)ncnc32)C(O)C1O)OCc1ccccc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RY1 P47900 5/20 0.64
P2RY2 P41231 4/20 0.64
ADORA1 P30542 3/20 0.64
SRC P12931 2/20 0.64
SMN1; SMN2 Q16637 2/20 0.64
TAS1R3 Q7RTX0 2/20 0.64
TAS1R1 Q7RTX1 2/20 0.64
P2RY11 Q96G91 2/20 0.64
TRPM2 O94759 2/20 0.64
DNPH1 O43598 1/20 0.64
PRKAB2 O43741 1/20 0.64
LDHA P00338 1/20 0.64
ADRB2 P07550 1/20 0.64
FBP1 P09467 1/20 0.64
PRKAG1 P54619 1/20 0.64
PRKAA2 P54646 1/20 0.64
PDE4D Q08499 1/20 0.64
KCNH2 Q12809 1/20 0.64
PRKAA1 Q13131 1/20 0.64
PDE3A Q14432 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22402627 0.93 ENPP1 (0.71) P2RY1P2RY2ADORA1SRCSMN1; SMN2
SCHEMBL23922227 0.93 ENPP1 (0.71) P2RY1P2RY2ADORA1SRCSMN1; SMN2
SCHEMBL22393104 0.92 ENPP1 (0.72) P2RY1P2RY2ADORA1SRCSMN1; SMN2
SCHEMBL26937428 0.88 P2RY1 (0.59) P2RY1P2RY2ADORA1SRCSMN1; SMN2
SCHEMBL30592500 0.88 P2RY1 (0.59) P2RY1P2RY2ADORA1SRCSMN1; SMN2
SCHEMBL26361381 0.88 P2RY1 (0.59) P2RY1P2RY2ADORA1SRCSMN1; SMN2
SCHEMBL109340 0.88 P2RY1 (0.72) P2RY1P2RY2ADORA1SRCSMN1; SMN2
SCHEMBL23922254 0.87 P2RX3 (0.58) P2RY1P2RY2ADORA1SRCSMN1; SMN2
SCHEMBL13614594 0.85 P2RY1 (0.83) P2RY1P2RY2ADORA1SRCSMN1; SMN2
SCHEMBL14017387 0.85 P2RY1 (0.83) P2RY1P2RY2ADORA1SRCSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11840551-B2 Compositions and methods of modulating the immune response by activating alpha protein kinase 1 SHANGHAI YAO YUAN BIOTECHNOLOGY CO., LTD. (CN) 2023-12-12 US disclosed
US-20220017560-A1 COMPOSITIONS AND METHODS OF MODULATING THE IMMUNE RESPONSE BY ACTIVATING ALPHA PROTEIN KINASE 1 WUXI PHARMATECH HEALTHCARE FUND I L.P. (CN) 2022-01-20 US disclosed
US-11149051-B2 Compositions and methods of modulating the immune response by activating alpha protein kinase 1 SHANGHAI YAO YUAN BIOTECHNOLOGY CO., LTD. (CN) 2021-10-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220017560-A1 COMPOSITIONS AND METHODS OF MODULATING THE IMMUNE RESPONSE BY ACTIVATING ALPHA PROTEIN KINASE 1 PHKA1, PHKA2, PRKCA P2RY1 561/4885P2RY2 796/4885ADORA1 344/4885
US-11149051-B2 Compositions and methods of modulating the immune response by activating alpha protein kinase 1 PHKA1, PHKA2, PRKCA P2RY1 561/4885P2RY2 796/4885ADORA1 344/4885
US-11840551-B2 Compositions and methods of modulating the immune response by activating alpha protein kinase 1 PHKA1, PHKA2, PRKCA P2RY1 561/4885P2RY2 796/4885ADORA1 344/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.